Torrance G - Search Results

1

Weinstein MC, Torrance G, McGuire A. Weinstein MC, et al. Among authors: torrance g. Value Health. 2009 Mar;12 Suppl 1:S5-9. doi: 10.1111/j.1524-4733.2009.00515.x. Value Health. 2009. PMID: 19250132 Free article. No abstract available.

2

Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group.

Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG Jr, Torrance GW. Weinstein MC, et al. Among authors: torrance gw. Health Econ. 1997 Sep-Oct;6(5):505-10. doi: 10.1002/(sici)1099-1050(199709)6:5<505::aid-hec294>3.0.co;2-i. Health Econ. 1997. PMID: 9353651 No abstract available.

3

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.

Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Siegel JE, et al. Among authors: torrance gw. Pharmacoeconomics. 1997 Feb;11(2):159-68. doi: 10.2165/00019053-199711020-00005. Pharmacoeconomics. 1997. PMID: 10172935 Review.

4

Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.

Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, La Forge J, Lampron N. Torrance G, et al. Pharmacoeconomics. 1999 Nov;16(5 Pt 1):499-520. doi: 10.2165/00019053-199916050-00007. Pharmacoeconomics. 1999. PMID: 10662396 Clinical Trial.

5

The development and use of quality-of-life measures to evaluate health outcomes in Japan.

Fukuhara S, Ikegami N, Torrance GW, Nishimura S, Drummond M, Schubert F. Fukuhara S, et al. Pharmacoeconomics. 2002;20 Suppl 2:17-23. doi: 10.2165/00019053-200220002-00003. Pharmacoeconomics. 2002. PMID: 12238945 Review.

6

Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Ikegami N, Drummond M, Fukuhara S, Nishimura S, Torrance GW, Schubert F. Ikegami N, et al. Pharmacoeconomics. 2002;20 Suppl 2:1-7. doi: 10.2165/00019053-200220002-00001. Pharmacoeconomics. 2002. PMID: 12238943 Review.

7

Validation of a prediction model to estimate health utilities index Mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the hip.

Marshall D, Pericak D, Grootendorst P, Gooch K, Faris P, Frank C, Bellamy N, Torrance G, Feeny D. Marshall D, et al. Among authors: torrance g. Value Health. 2008 May-Jun;11(3):470-7. doi: 10.1111/j.1524-4733.2007.00258.x. Value Health. 2008. PMID: 18489670 Free article.

8

Utility measurement in healthcare: the things I never got to.

Torrance GW. Torrance GW. Pharmacoeconomics. 2006;24(11):1069-78. doi: 10.2165/00019053-200624110-00004. Pharmacoeconomics. 2006. PMID: 17067192 Review.

9

Incorporating Mortality in Health Utility Measures.

Dewitt B, Torrance GW. Dewitt B, et al. Among authors: torrance gw. Med Decis Making. 2020 Oct;40(7):862-872. doi: 10.1177/0272989X20951778. Epub 2020 Sep 30. Med Decis Making. 2020. PMID: 32996355

10

Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.

Rosner AJ, Grima DT, Torrance GW, Bradley C, Adachi JD, Sebaldt RJ, Willison DJ. Rosner AJ, et al. Among authors: torrance gw. Pharmacoeconomics. 1998 Nov;14(5):559-73. doi: 10.2165/00019053-199814050-00007. Pharmacoeconomics. 1998. PMID: 10344918

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

129 results

Search Page